Close

Jump to:

  • Navigation
  • Content
  • Footer
Future You Cambridge hero image

Future You Cambridge

Follow

D2C health supplements clinically proven to deliver more of the good stuff to your body.

118%
 - 
Funded 27 Jun 2020
£550,001 target
£655,011 from 193 investors
More
Less

Business overview

Location Cambridge, United Kingdom
Social media
Website futureyouhealth.com/
Sectors Healthcare Mixed Digital/Non-Digital Mixed B2B/B2C
Company number 07322398
Incorporation date 22 Jul 2010
More
Less

Investment summary

Type Equity
Valuation (pre-money) £8.1M
Equity offered 7.46%
Tax relief

EIS

More
Less

Business highlights

  • Served more than 100,000 customers
  • £4m+ annual revenue*
  • £3m+ in annual recurring subscription revenue*
  • More than 20x D2C revenue growth over last 4 years*
More
Less

Key features

  • Secondary Market
  • Seedrs nominee min. £10.80 +
  • Pay by Bank payments not accepted
  • Idea
  • Key information
  • Team
  • Updates
  • Investors 193
  • Discussion
  • Documents

Idea

Introduction

We sell clinically proven health supplements which improve lives, direct to consumers.

The health supplement sector has plenty of products, but little evidence of which products work, and which ones are right for you. This creates a confusing space for customers to navigate.

Our supplements work, and our customers evidence this by buying on subscription time and time again and by telling us their transformational stories.

Covid-19 has heightened consumers' awareness of the fact that we all need to take responsibility for our own health. At FutureYou Cambridge, we are investing in expanding our product ranges to serve even more people, as well as providing better digital tools to help our customers find the products they need.

Since we launched our brand, FutureYou Cambridge in 2016 we have sold to over 100,000 customers.

Substantial accomplishments to date

Built an experienced, heavyweight management team and board of directors, as well as an expert scientific advisory panel.

Consistently backed by influential private investors since our journey began in 2015.

IP-rich product base. Our key Lactolycopene patent was granted in Dec-2017.

Dedicated to high-quality products that produce scientifically proven results. For example, a clinical paper published in the European Journal of Nutrition in Oct-2019 showed that one of our Lactolycopene products (Fertility+) resulted in a 40% increase in fast-swimming sperm. Recognised in press worldwide.

Our in-house developed, bespoke, powerful, subscription management system is best in class.

First-class data analysis is central to our business success and informs everything we do.

Product range now at 24 products, including a popular CBD product and our first product for pets, Curcupet-K9 with 10+ further products planned to come in 2020.

Proven platform scalability, with >20x direct-to-consumer (DTC) revenue growth over the past 4 years, reaching total revenue of £4m+ in 2019*. We have now served >130,000 customers.

80% of our DTC revenue is repeating monthly subscription sales from our highly loyal customer base.

We have an industry-leading customer care team, winning the 2018 Cambridge Service Excellence and Independent High Growth Business of the Year awards.

Our 5-star Trustpilot review rating is testament to our first-rate customer service and high-quality products.

Monetisation strategy

Around 90% of our sales are direct to consumer, with orders placed either through our website, by ongoing monthly subscription, or in some cases over the phone.

80% of our DTC revenue is from customers who have taken out a subscription. Although they can cancel at any time (and we make cancelling incredibly easy for them), they tend to be extremely loyal and consequently we see very high customer lifetime values.

As we have expended our product ranges and improved our targeted marketing messages, we see an increasing number of customers now purchasing more than one product from us.

We also sell to a few international partners in much larger, B2B transactions. Unlike D2C where transactions are typically £10-30, the scale of these transactions is £10,000-100,000 and they are less frequent. We aim to expand the list of partners we work with in overseas territories.

Use of proceeds

The business has no outstanding debt.

Funding is primarily allocated to scaling up direct advertising campaigns that already have great customer acquisition metrics, to further accelerate our business' growth.

We intend to expand our product range by more than 10 new products over the next twelve months, addressing two new customer segments, as well as expanding our offering across our existing segments. We believe that this will require an investment of £200,000 in additional inventory.

We also invest heavily in our website technology and have some exciting tools planned for customers to help them find the perfect supplements coming up in the next few months.

Based on scalability to date, we believe that doubling our revenue will require very few additional heads.

* Based on unaudited management accounts.

Key information

Nestec agreements

The company has two agreements with Nestec, a subsidiary of the Nestle Group: a license agreement and an option agreement.
Licence Agreement:

• The agreement provides for mutual licensing arrangements between the Company and Nestec in respect of various patents held by both companies.
• Under these licences, the company pays a 5% royalty to Nestec on sales from products making up about 10% of overall revenue.
• To date, the company has never received any royalties from Nestec.

Option Agreement:
• The Nestec Option Agreement entitles Nestec to acquire up to 15% of the issued share capital of the Company (by way of new share issue) for a payment of up to £1.5m based on a £10m company valuation. The resultant Nestec maximum holding will be less than 15%, however, as it will be diluted by the issue of the Nestec shares themselves. Exercise of this option will dilute investors.

The licence agreement and the option agreement remain in force until the final patent expires on 13 April 2026.

Open an account to get access to the team members of Future You Cambridge

Sign up

Already have an account? Log in

To comply with financial regulations, we can only show full campaign details to registered users.

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Only shareholders can access this page

If you successfully purchase a share lot of this business, you will be granted access.

Buy shares

Share on:

Investing carries risks, including loss of capital and illiquidity. Please read our Risk Warning before investing.

Investing involves risks, including loss of capital, illiquidity, lack of dividends and dilution, and should be done only as part of a diversified portfolio. Please read the Risk Warnings before investing. Investments should only be made by investors who understand these risks. Tax treatment depends on individual circumstances and is subject to change in future.

This webpage has been approved as a financial promotion by Seedrs Limited ("Seedrs"), which is authorised and regulated by the Financial Conduct Authority. It is not intended to be a promotion of any individual investment opportunity and is not an offer to the public. The summary information provided about investment opportunities on this webpage is intended solely to demonstrate the types of investments available on the Seedrs platform, and any investment decision should be made on the basis of the full campaign. Full campaigns are available to investors who have become authorised to invest on the Seedrs platform. All investment activities take place within the United Kingdom, and any person resident outside the United Kingdom should ensure that they are not subject to any local regulations before investing.

Seedrs does not make investment recommendations to you. No communications from Seedrs, through this website or any other medium, should be construed as an investment recommendation. Further, nothing on this website shall be considered an offer to sell, or a solicitation of an offer to buy, any security to any person in any jurisdiction to whom or in which such offer, solicitation or sale is unlawful. Seedrs does not provide legal, financial or tax advice of any kind. If you have any questions with respect to legal, financial or tax matters relevant to your interactions with Seedrs, you should consult a professional adviser.

Tax Relief (SEIS)

This business is eligible for SEIS relief - providing qualifying investors with income tax relief of 50% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Tax Relief (EIS)

This business is eligible for EIS relief - providing qualifying investors with income tax relief of 30% of their investment and certain other tax reliefs. Tax treatment depends on individual circumstances and is subject to change in future. Click to learn more.

Valuation (pre-money)

Valuation rounded from £8,108,776

Pitch type

There are 5 types of investment pitch available on Seedrs.

  • Equity
  • Convertible
  • Fund
  • Cohort
  • Secondary

Investing in a regular equity campaign is the simplest and most common way to invest in a startup. You decide which business you want to invest in, and if the campaign hits its funding target then you will become one of their shareholders. As the company becomes more valuable, so do your shares; allowing you the opportunity to share in the future success of the business.

Learn more about pitch type on Seedrs

Seedrs nominee

This shows if you are able to choose, when making an investment, that you be represented by, and your shareholding be managed by, the Seedrs nominee.

Find out more

Custodian

If you invest in this Campaign, Seedrs will act as Custodian rather than provide our standard nominee service. This is due to the fact that the business is not directly involved in the share sale and Seedrs will not benefit from any rights under a shareholder agreement. As a result, Seedrs will handle administrative tasks as we do normally, but you will not have information or voting rights, updates from the business, preemption on future fundraising, or ongoing support about business trading activity.

Learn more about Custodian here

Secondary market

This shows if the business has opted-in or opted-out of allowing its shares to be bought and sold on the secondary market.

Find out more

Direct investment

This shareholding type is available and the minimum investment required to select it.

Find out more

Payment options

We are not able to accept card payments for investments into this sector. You can pay for your investment by creating a bank transfer, using funds in your investment account or create a Pay by Bank payment. Your investment will only be completed once the funds have reached our account.

Business Involvement

This Campaign offers shares for sale in business that is not directly involved in this Campaign or the sale. As a result, the Campaign and post-investment experience, including investor rights, will differ from a business-led campaign on Seedrs. Most notably, the business will not engage with investors in the discussion forums both during and after the sale or provide any updates to investors.

Learn more here

Payment options

We are not able to accept Pay by Bank payments for investments into this sector. You can pay for your investment with a card payment, by creating a bank transfer or by using funds in your investment account. Your investment will only be completed once the funds have reached our account.

Drawdowns

This campaign offers the ability to pay for an investment by drawdowns.